share_log

康希諾生物：截至2024年3月31日止三個月的第一季度報告

CANSINOBIO: FIRST QUARTERLY REPORT FOR THETHREE MONTHS ENDED MARCH 31, 2024

HKEX ·  Apr 29 21:59

Summary by Moomoo AI

康希諾生物於2024年4月29日發布截至2024年3月31日止三個月的未經審計第一季度報告。報告顯示，公司營業收入為1.14億元人民幣，同比增長13.65%。然而，公司歸屬於上市公司股東的淨虧損為1.7億元人民幣，基本每股收益為負0.69元。研發投入合計為1.24億元人民幣，佔營業收入的比例為108.79%，較去年同期減少41.25個百分點。公司總資產為85.69億元人民幣，較上年度末減少8.05%。本季度，由於上藥康希諾不再納入合併範圍，公司總資產和總負債下降，產生投資損失約7051萬元人民幣。此外，公司於2024年3月收到巴西法院送達的訴訟材料，涉及約1.67億雷亞爾（約合人民幣2.41億元）的賠償請求，公司已聘請專業律師團隊應對訴訟。報告期末普通股股東總數為21,770名。
康希諾生物於2024年4月29日發布截至2024年3月31日止三個月的未經審計第一季度報告。報告顯示，公司營業收入為1.14億元人民幣，同比增長13.65%。然而，公司歸屬於上市公司股東的淨虧損為1.7億元人民幣，基本每股收益為負0.69元。研發投入合計為1.24億元人民幣，佔營業收入的比例為108.79%，較去年同期減少41.25個百分點。公司總資產為85.69億元人民幣，較上年度末減少8.05%。本季度，由於上藥康希諾不再納入合併範圍，公司總資產和總負債下降，產生投資損失約7051萬元人民幣。此外，公司於2024年3月收到巴西法院送達的訴訟材料，涉及約1.67億雷亞爾（約合人民幣2.41億元）的賠償請求，公司已聘請專業律師團隊應對訴訟。報告期末普通股股東總數為21,770名。
Conchinobio released on April 29, 2024 its unaudited first quarter report for the three months ended March 31, 2024. The report showed that the company's operating income was RMB 1.14 billion, an increase of 13.65% year-on-year. However, the company had a net loss attributable to shareholders of listed companies of RMB 1.7 billion and basic earnings per share of negative $0.69. R&D investments totaled RMB 1.24 billion and accounted for 108.79% of operating income, down 41.25 percentage points from the same period last year. The company's total assets were RMB85.69 billion, down 8.05% year-on-year. In the quarter, the company's total assets and total liabilities decreased, resulting in an investment loss of approximately RMB 7051 million, as the drug was no longer included in the merger scope...Show More
Conchinobio released on April 29, 2024 its unaudited first quarter report for the three months ended March 31, 2024. The report showed that the company's operating income was RMB 1.14 billion, an increase of 13.65% year-on-year. However, the company had a net loss attributable to shareholders of listed companies of RMB 1.7 billion and basic earnings per share of negative $0.69. R&D investments totaled RMB 1.24 billion and accounted for 108.79% of operating income, down 41.25 percentage points from the same period last year. The company's total assets were RMB85.69 billion, down 8.05% year-on-year. In the quarter, the company's total assets and total liabilities decreased, resulting in an investment loss of approximately RMB 7051 million, as the drug was no longer included in the merger scope. In addition, in March 2024, the company received litigation materials submitted to a Brazilian court, involving a claim for compensation of approximately 1,67 billion reais (approximately RMB2.41 million), and the company has hired a team of professional lawyers to handle the lawsuit. The total number of ordinary shareholders at the end of the reporting period was 21,770.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated